证券代码：600056 证券简称：中国医药 公告编号：临2025-057号 中国医药健康产业股份有限公司 第九届董事会第 29 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第29次 会议（以下简称"本次会议"）于2025年7月23日以现场结合通讯方式召开，会议由 董事长杨光先生主持，公司监事及相关高级管理人员列席了本次会议。 (二)本次会议通知于2025年7月18日以邮件、短信、电话或传真的方式向全体董 事发出。 (三)本次会议应当出席董事7名，实际出席会议的董事7名。 (四)本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议为 有效决议。 二、会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于制定<市值管理制度>的议案》。 制度全文详见上海证券交易所网站（www.sse.com.cn）。 （二）审议通过了《关于设立大健康和电商事业部暨调整内设机构的议案》。 经决议，董事会同意公司设立大健康和电商 ...

Industry Overview - Pharmaceutical distribution connects upstream manufacturers with downstream distributors and end customers, involving procurement from manufacturers and wholesale to distributors or direct sales to retail outlets like hospitals and pharmacies [1][3] - The distribution process is divided into two main segments: wholesale, characterized by large volumes and low margins, and retail, which has higher margins and sales costs [1] Industry Chain Analysis - The pharmaceutical distribution chain includes three segments: drug wholesale, retail enterprises, and hospital outpatient pharmacies, with hospital pharmacies holding a monopolistic position in the market [3] Industry Development History - The pharmaceutical distribution industry in China has undergone several transformations, from a planned economy system to a competitive regional structure, and now to a more concentrated market post "Two Invoice System" reform [6][7] Current Industry Status - The pharmaceutical circulation market has exceeded 3 trillion yuan, with a projected growth of 4.4% in 2024 [15] - State-owned enterprises dominate the pharmaceutical distribution sector, accounting for 61.8% of total revenue among reporting enterprises [20] - The B2B segment constitutes 50% of the pharmaceutical e-commerce market, indicating a significant focus on wholesale transactions [25] Competitive Landscape - The market is segmented into three tiers based on sales scale, with major national wholesalers like China National Pharmaceutical Group and Shanghai Pharmaceuticals leading the first tier [28] Future Development Trends - The pharmaceutical distribution market is expected to surpass 4 trillion yuan by 2030, driven by increased concentration, reduced distribution costs, and improved drug quality and safety [30] - The industry is moving towards greater integration and information technology adoption, enhancing service capabilities and efficiency [33]

证券代码：600056 证券简称：中国医药 公告编号：临2025-056号 中国医药健康产业股份有限公司 关于董事、总经理辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）董事会收到董事、 总经理胡慧冬女士的书面辞职报告。因工作调整原因，胡慧冬女士申请辞去公司董 事、董事会专门委员会委员及总经理职务，并将不再担任公司任何职务。截至本公 告披露日，胡慧冬女士未持有公司股票。 根据《公司章程》规定，胡慧冬女士的辞职未造成公司董事会低于法定人数， 其辞职报告自送达董事会时生效。公司将尽快按照法定程序完成新任董事、总经理 的选举和聘任工作。 公司及董事会对胡慧冬女士在任职期间为公司发展所做出的卓越贡献表示衷心 的感谢！ 特此公告。 中国医药健康产业股份有限公司董事会 2025 年 7 月 18 日 ...

Core Insights - The conference focuses on the integration of technology and business in the healthcare finance sector, particularly emphasizing the application of AI and other digital technologies [1] Group 1: Conference Overview - The 2025 Fifth China Hospital Accounting Conference is organized by the Chinese Medical Accounting Society and other institutions, aiming to create a platform for deep integration of technology and business [1] - The conference features participation from government officials, industry experts, and academic leaders to discuss advancements in healthcare finance [1] Group 2: Importance of Financial Management - The president of the Shanghai Jiao Tong University School of Medicine, Ning Guang, highlighted the critical role of financial management in hospital operations, asserting that strong financial management is essential for effective healthcare delivery [1] - Financial management is positioned as a core component of hospital management, necessary for economic operations and sustainability [1] Group 3: Technological Applications - The president of the Medical Finance Policy Branch of the Chinese Medical Accounting Society, Li Xuehui, discussed the significance of AI, big data, and cloud computing in transforming healthcare finance [1] - Liu Qin, director of the Intelligent Finance Research Institute at the Shanghai National Accounting Institute, presented on the development and challenges of intelligent finance, emphasizing the need for practical application scenarios [1]

Core Viewpoint - A groundbreaking oral nutritional supplement, "Dr. End PQQ Dihydroquercetin Compound Peptide Effervescent Tablets," developed by the Seiko Telomere Programming Laboratory in collaboration with Harvard Anti-Aging and Anti-Cancer Research Center, is set to launch globally in August 2025, marking a significant advancement in the field of immune modulation and anti-aging cancer prevention [1][7]. Group 1: Product Development and Technology - The product utilizes "Functional Modulation NK Cells" technology to precisely regulate the activity of endogenous NK cells, aiming to restore immune balance and address the decline in NK cell quantity and activity due to aging and environmental factors [3][5]. - The supplement is backed by multiple top-tier invention patents, with international patents in the anti-aging and anti-cancer fields already granted, establishing a strong technological barrier and global leadership [1][5]. Group 2: Clinical Trials and Efficacy - A clinical trial involving 586 participants aged 45-65 demonstrated a significant increase in endogenous NK cell quantity and activity, with an average improvement rate of 21.3% after 24 weeks of continuous use [5]. - The product's safety and reliability are enhanced as it activates the body's endogenous NK cells without external interference, contrasting with the risks associated with exogenous NK cell activation therapies [5][6]. Group 3: Market Launch and Global Impact - The product will be marketed globally by Seiko Pharmaceutical Technology (Jiangsu) Co., Ltd., through the "Dr. End Health Happy Mall," highlighting a milestone in the biopharmaceutical industry and a historic breakthrough in immune modulation and anti-aging cancer prevention [7]. - This launch is expected to inject significant momentum into global health and well-being, ushering in a new era of precise immune protection [7].

Core Viewpoint - The continuous implementation of centralized drug procurement in China is reshaping the pharmaceutical industry, pushing traditional companies towards efficiency, innovation, and international expansion to ensure sustainable development [1][2]. Group 1: Centralized Drug Procurement - The National Healthcare Security Administration has conducted the tenth batch of centralized drug procurement, involving 62 types of drugs, bringing the total to 435 since 2018 [1]. - Experts indicate that the normalization of centralized procurement is forcing traditional pharmaceutical companies to abandon simple expansion strategies and adapt to a more efficient and innovative operational model [1][2]. Group 2: Cost Control and Efficiency - Centralized procurement has significantly reduced drug prices by compressing the price margins in the distribution chain, compelling traditional companies to optimize costs and build a lean management system across the entire industry chain [2]. - Companies like Jiangsu Jibeier Pharmaceutical have implemented strict procurement management systems to control costs, while Health元药业 has integrated AI technology to enhance production efficiency and reduce risks [2]. Group 3: Research and Development - 博瑞医药 has increased its R&D investment in innovative drugs and inhalation formulations to 62.78% of total R&D spending, a year-on-year increase of 77.37% [3]. - The shift from scale expansion to lean survival is seen as a long-term strategic choice for traditional pharmaceutical companies, emphasizing the importance of genuine innovation for sustainable growth [3][4]. Group 4: Innovation and Market Position - Traditional pharmaceutical companies are increasingly focusing on developing innovative drugs and high-barrier generic drugs to transition from reliance on low-cost generics [4]. - 恒瑞医药 has invested 46 billion yuan in R&D since 2011, achieving significant milestones in innovative drug approvals and clinical trials [5]. Group 5: International Expansion - Chinese pharmaceutical companies are becoming key players in the global market, with over 90 licensing transactions completed in 2024, totaling over 50 billion USD [7]. - The trend of "going global" is driven by enhanced R&D capabilities and favorable external conditions, allowing companies to compete effectively on the international stage [7][8].

Market Overview - The Shanghai Composite Index closed at 3519.65 points, above the annual line, with a change of 0.27% [1] - The total trading volume of A-shares reached 14809.22 billion yuan [1] Stocks Breaking Annual Line - A total of 46 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Huaming Equipment (002270) with a deviation rate of 2.75% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.63% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, latest price 76.99 yuan, deviation rate 7.62% - Huaming Equipment: 3.25% increase, latest price 16.85 yuan, deviation rate 2.75% - Tongyi Co., Ltd.: 2.63% increase, latest price 16.02 yuan, deviation rate 2.63% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Daqin Railway and *ST Haiyuan with minimal deviation rates [1]

Market Overview - The Shanghai Composite Index closed at 3525.40 points, above the annual line, with a change of 0.43% [1] - The total trading volume of A-shares reached 987.43 billion yuan [1] Stocks Breaking Annual Line - A total of 41 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.51% - Ruisheng Technology (688090) with a deviation rate of 2.05% [1] Stocks with Significant Deviation Rates - The stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, trading at 76.99 yuan - Tongyi Co., Ltd.: 2.50% increase, trading at 16.00 yuan - Ruisheng Technology: 3.24% increase, trading at 35.10 yuan [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Qianjiang Motorcycle, Jiuquan Technology, and Huadian International, which have just reached the annual line [1]

Group 1 - The legal opinion letter confirms that the procedures for convening and holding the shareholders' meeting comply with the Company Law, Shareholders' Meeting Rules, and the company's articles of association [2][3][5] - The shareholders' meeting was scheduled for July 11, 2025, with a registration date of July 3, 2025, and utilized both a physical meeting and an online voting system [2][3] - A total of 1,213 shareholders participated in the online voting, representing 154,915,116 shares, which is 10.3561% of the total voting shares [3][4] Group 2 - The voting results showed that 152,045,883 shares were in favor of the proposals, accounting for 98.1478% of the valid votes cast [5] - Among minority investors, 12,045,883 shares voted in favor, representing 80.7629% of the valid votes from this group [5] - The legal opinion concludes that the meeting's procedures, participant qualifications, voting methods, and results are all valid and comply with relevant laws and regulations [5][6]

近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的福多司坦片（以下简称"该药品"）《药品注 册证书》，现将有关情况公告如下： 一、注册证书基本信息 药品名称：福多司坦片 受理号：CYHS2302051 证书编号：2025S02096 剂型：片剂 证券代码：600056 证券简称：中国医药 公告编号：临 2025-054 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 规格：0.2g 上市许可持有人：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 （一）福多司坦片由日本三菱制药株式会社研制，于 2001 年 12 月在日本上 市。临床主要用于支气管哮喘、慢性喘息性支气管炎、支气管扩张、肺结核、尘 肺、慢性阻塞性肺气肿、非典型分枝杆菌 ...